Paper offers a lesson that more data doesn't always mean more learnings, says safety guru

17 October 2019

When the US Food and Drug Administration (FDA) found that it was in danger of drowning in the volume of safety reports being submitted relating to approved therapies, the agency brought in Transcelerate BioPharma to help.

This US non-profit, which brings together members of the research and development community to help find solutions that lead to better, safer medicines reaching patients, brought together a pharma consortium to take on pharmacovigilance as an area of high priority.

Peter Verdu (pictured above), former head of patient safety at Belgian drugmaker UCB (Euronext: UCB) and now a consultant with PVMD2, was one of five authors of a paper subsequently published on the issue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK